183208-32-4

Usage

Uses

Used in Chemical Synthesis:
3,3,5-Tribromo-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is used as an intermediate compound for the synthesis of more complex molecules. Its unique structure with a pyrrole ring fused to a pyridine ring and the presence of bromine atoms make it a valuable building block in the creation of novel chemical entities.
Used in Pharmaceuticals:
3,3,5-Tribromo-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is used as a potential pharmaceutical candidate due to its heterocyclic nature. The presence of bromine atoms and the carbonyl group may contribute to its biological activity, making it a candidate for further research and development in the field of drug discovery.
Used in Materials Science:
3,3,5-Tribromo-1H-pyrrolo[2,3-b]pyridin-2(3H)-one is used as a component in the development of new materials with specific properties. Its heterocyclic structure and functional groups may impart unique characteristics to materials, such as improved stability, reactivity, or conductivity, making it a valuable asset in materials science research.

InChI:InChI=1/C7H3Br3N2O/c8-3-1-4-5(11-2-3)12-6(13)7(4,9)10/h1-2H,(H,11,12,13)

Upstream product

• 271-63-6 7-Azaindole 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 113423-51-1 3,3-Dibromo-1,3-dihydro-2H-pyrrolo[2,3-b]-pyridin-2-one 

Downstream Products

• 1229584-03-5 5-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one 
• 1207623-97-9 5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1,3-dihydropyrrolo[2,3-b]pyridin-2-one 
• 1443684-48-7 2-(2,6-difluoro-phenyl)-5-(5-ethyl-2-pyridin-3-yl-thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1443684-79-4 2-(2,6-difluoro-phenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1443684-39-6 2-(2,6-difluoro-phenyl)-5-(2-ethyl-5-pyridin-3-yl-2H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1443684-78-3 2-(2,6-difluoro-phenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 1443684-36-3 4-[2-(2,6-difluoro-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-3-methyl-benzoic acid methyl ester 
• 1443684-77-2 2-(2,6-difluoro-phenyl)-5-(4-methoxycarbonyl-2-methyl-phenyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 1443684-76-1 5-bromo-2-(2,6-difluoro-phenyl)-1H-pyrrolo[2,3-b]pyridine 
• 1443684-75-0 5-bromo-2-(2,6-difluoro-phenyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 1443684-73-8 5-bromo-2-oxo-2,3-dihydro-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 1443684-72-7 5-bromo-2-ethoxycarbonyloxy-pyrrolo[2,3-b]pyridine-1-carboxylic acid ethyl ester 
• 183208-22-2 5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine 
• 183208-38-0 3-formyl-5-methoxy-1H-pyrrolo<2,3-b>pyridine 

Relevant academic research and scientific papers

Application of 7-azaisatins in enantioselective Morita-Baylis-Hillman reaction

7-Azaisatin and 7-azaoxindole skeletons are valuable building blocks in diverse biologically active substances. Here 7-azaisatins turned out to be more efficient electrophiles than the analogous isatins in the enantioselective Morita-Baylis-Hillman (MBH) reactions with maleimides using a bifunctional tertiary amine, β-isocupreidine (β-ICD), as the catalyst. This route allows a convenient approach to access multifunctional 3-hydroxy-7-aza-2-oxindoles with high enantiopurity (up to 94% ee). Other types of activated alkenes, such as acrylates and acrolein, could also be efficiently utilized.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Synthesizing method of 5-bromine-1H-pyrrolo[2,3-b]pyridine

The invention particularly relates to a synthesizing method of 5-bromine-1H-pyrrolo[2,3-b]pyridine. The synthesizing method is characterized in that 1H-pyrrolo[2,3-b]pyridine is dissolved in a solvent to have bromination reaction with a brominating agent under 5-40 DEG C, and reductive dehalogenation is performed under 20-50 DEG C after the bromination reaction to obtain 5-bromine-1,3-dihydro-2H-pyrrolo[2,3-b]pyridine-2-ketone; under the effect of a reducing agent, the 5-bromine-1,3-dihydro-2H-pyrrolo[2,3-b]pyridine-2-ketone has reduction reaction in a certain solvent under 25-40 DEG C, and oxidative dehydrogenation is performed at 25-60 DEG C after the reduction reaction to obtain the 5-bromine-1H-pyrrolo[2,3-b]pyridine. The synthesizing method has the advantages that the method is simple in reaction step and mild in reaction condition, the four-step reaction is simplified into two one-pot two-step reactions, the treatment process is simplified, and the use amount of organic solvents is reduced.

Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors

Five novel 1H-pyrrolo[2,3-b]pyridine or 1H-pyrazolo[3,4-b]pyridine derivatives, with a methylene, sulfur, sulfoxide or cyclopropyl group as a linker, were designed, synthesized and biologically evaluated against c-Met and ALK. The development of these methods of compound synthesis may provide an important reference for the construction of novel 7-azaindole and 7-azaindazole derivatives with a single atom linker. The enzyme assay and cell assay in vitro showed that compound 9 displayed strong c-Met kinase inhibition with IC50 of 22.8 nM, moderate ALK kinase inhibition, and strong cell inhibition with MKN-45 IC50 of 329 nM and EBC-1 IC50 of 479 nM. In order to find the better candidate compounds, compounds 8, 9 and 10 have been selected as tool compounds for further optimization.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

New bicyclic compounds as crac channel modulators

The present invention relates to novel compounds which are inhibitors of CRAC channel activity. This invention also relates to pharmaceutical compositions containing them, process for their preparation and their use in therapy.

7-AZAINDOLE INHIBITORS OF CRAC

Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Synthesis of 7-azaserotonin: Its photophysical properties associated with excited state proton transfer reaction

We report the synthesis of 3-(2-aminoethyl)-5-ol-1H-pyrrolo[2,3-b]pyridine (7-azaserotonin), which may potentially serve as an agonist or antagonist of serotonin receptors. In alcohols, the solvent (e.g., ethanol) catalyzed proton-transfer reaction takes place for 7-azaserotonin in the excited state, resulting in dual emission. Conversely, excited-state deprotonation takes place in neutral aqueous solution. The unique excitation behavior makes 7-azaserotonin versatile as a potential bioprobe. Copyright